EQT Leads Investment in Mosanna to Advance Nasal Spray Therapy for Sleep Apnea Patients

EQT Leads Investment in Mosanna to Advance Nasal Spray Therapy for Sleep Apnea Patients

Open the article to view the coverage from EuropaWire.eu

Mosanna Therapeutics secures $80m in funding

Mosanna Therapeutics has secured $80m in a Series A funding round for advancing new nighttime nasal spray for obstructive sleep apnoea (OSA).

Mosanna Therapeutics NV bags $80m in Series A round - European Biotechnology Magazine

Dutch obstructive sleep apnea (OSA) specialist Mosanna Therapeutics NV has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118. The post Mosanna Therapeutics NV bags $80m in Series A round appeared first on European Biotechnology Magazine.

Mosanna Therapeutics raises €70.1M to disrupt sleep apnea treatment with nasal spray - Silicon Canals

Mosanna Therapeutics, a biotech company specialised in the treatment of obstructive sleep apnea (OSA), has secured $80M (approximately €70.1M) in Series A funding. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures, and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).  HTGF i…